Lifecore Biomedical, Inc. De (LFCR) EBITDA Margin (2010 - 2025)

Lifecore Biomedical's EBITDA Margin history runs 16 years deep, the most recent figure standing at 14.62% for Q2 2025.

• In Q2 2025, EBITDA Margin rose 894.0% year-over-year to 14.62%; the TTM figure through May 2025 stood at 13.38% (down 2995.0% YoY), while the FY2025 annual figure was 13.38%, down 649.0% from the prior year.
• EBITDA Margin was 14.62% for Q2 2025 at Lifecore Biomedical, up from 25.68% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 47.16% in Q4 2023 to a low of 149.47% in Q4 2021.
• Historically, EBITDA Margin has averaged 30.08% across 5 years, with a median of 23.5% in 2023.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin tumbled 10073 bps in 2023, then jumped 18136 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 149.47% in 2021, then soared by 62 bps to 57.26% in 2022, then soared by 182 bps to 47.16% in 2023, then sank by 113 bps to 6.02% in 2024, then surged by 343 bps to 14.62% in 2025.
• The last three EBITDA Margin figures came in at 14.62% (Q2 2025), 25.68% (Q1 2025), and 6.02% (Q4 2024), per Business Quant data.